1. Market Research
  2. > Schizoaffective Disorder - Pipeline Review, H1 2013

Schizoaffective Disorder - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Schizoaffective Disorder - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Schizoaffective Disorder - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Schizoaffective Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizoaffective Disorder. Schizoaffective Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Schizoaffective Disorder.
- A review of the Schizoaffective Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Schizoaffective Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Schizoaffective Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Schizoaffective Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Schizoaffective Disorder - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Schizoaffective Disorder Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Schizoaffective Disorder 7
Schizoaffective Disorder Therapeutics under Development by Companies 9
Schizoaffective Disorder Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Schizoaffective Disorder Therapeutics - Products under Development by Companies 14
Schizoaffective Disorder Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Schizoaffective Disorder Therapeutics Development 16
Reviva Pharmaceuticals Inc. 16
Schizoaffective Disorder - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
cannabidiol - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
oxytocin - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
RP-5063 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Drugs Targeting NOS1AP - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Schizoaffective Disorder Therapeutics - Drug Profile Updates 27
Schizoaffective Disorder Therapeutics - Discontinued Products 28
Schizoaffective Disorder Therapeutics - Dormant Products 29
Schizoaffective Disorder - Product Development Milestones 30
Featured News and Press Releases 30
Apr 09, 2013: Reviva Pharma Reports Positive Top-Line Results From Phase II Study Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder 30
Jan 14, 2013: Reviva Pharma Completes Patient Enrollment In Phase II Trial Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder 31
Mar 12, 2012: Reviva Announces Enrollment Of Patients In Phase II Clinical Study Of RP5063 To Treat Schizophrenia And Schizoaffective Disorder 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables


Number of Products Under Development for Schizoaffective Disorder, H1 2013 7
Products under Development for Schizoaffective Disorder - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Reviva Pharmaceuticals Inc., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Schizoaffective Disorder Therapeutics - Drug Profile Updates 27
Schizoaffective Disorder Therapeutics - Discontinued Products 28
Schizoaffective Disorder Therapeutics - Dormant Products 29

List of Figures


Number of Products under Development for Schizoaffective Disorder, H1 2013 7
Products under Development for Schizoaffective Disorder - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.